Cited by 833CAR-T cell therapy researchCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

Open access

Rafiq, Sarwish, Yeku, Oladapo O, Jackson, Hollie J, Purdon, Terence J, van Leeuwen, Dayenne G, Drakes, Dylan J, Song, Mei, Miele, Matthew M, Li, Zhuoning, Wang, Pei, Yan, Su, Xiang, Jingyi, Ma, Xiaojing, Seshan, Venkatraman E, Hendrickson, Ronald C, Liu, Cheng, Brentjens, Renier J·2018·Nature Biotechnology

DOI 10.1038/nbt.4195PMC PMC6126939

Open this paper in CoChat — free account

Abstract

The efficacy of chimeric antigen receptor (CAR) T cell therapy against poorly responding tumors can be enhanced by administering the cells in combination with immune checkpoint blockade inhibitors. Alternatively, the CAR construct has been engineered to coexpress factors that boost CAR-T cell function in the tumor microenvironment. We modified CAR-T cells to secrete PD-1-blocking single-chain variable fragments (scFv). These scFv-secreting CAR-T cells acted in both a paracrine and autocrine manner to improve the anti-tumor activity of CAR-T cells and bystander tumor-specific T cells in clinically relevant syngeneic and xenogeneic mouse models of PD-L1+ hematologic and solid tumors. The efficacy was similar to or better than that achieved by combination therapy with CAR-T cells and a checkpoint inhibitor. This approach may improve safety, as the secreted scFvs remained localized to the tumor, protecting CAR-T cells from PD-1 inhibition, which could potentially avoid toxicities associated with systemic checkpoint inhibition.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nbt.4195

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
In-gel digestion for mass spectrometric characterization of proteins and proteomes
Shevchenko, A., Tomas, H., Havli, J., Olsen, J. V., & Mann, M. (2006) · Nature Protocols · doi:10.1038/nprot.2006.468 · Cited by 4,947
Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips
Rappsilber, J., Mann, M., & Ishihama, Y. (2007) · Nature Protocols · doi:10.1038/nprot.2007.261 · Cited by 4,641
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Self-citation
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089

Show all 46 references

Sorted by citations

Items 501–600 of 831

Alliance between titans: combination strategies of CAR-T cell therapy and oncolytic virus for the treatment of hematological malignancies
Gao, X., Liu, J., Sun, R., Zhang, J., Cao, X., Zhang, Y., & Zhao, M. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05488-9 · Cited by 10
Synthetic Cells and Molecules in Cellular Immunotherapy
Lin, H., Li, C., Zhang, W., Wu, B., Wang, Y., Wang, S., Wang, D., Li, X., & Huang, H. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.94346 · Cited by 10
PD-1-CD28-enhanced receptor and CD19 CAR-modified tumor-infiltrating T lymphocytes produce potential anti-tumor ability in solid tumors
Chen, X., Zhao, X., Mou, X., Zhao, J., Zhang, Z., Zhang, X., Huang, J., Liu, Y., Wang, F., Zhang, M., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116800 · Cited by 10
TYRP1 directed CAR T cells control tumor progression in preclinical melanoma models
Hackett, C. S., Hirschhorn, D., Tang, M. S., Purdon, T. J., Marouf, Y., Piersigilli, A., Agaram, N. P., Liu, C., Schad, S. E., de Stanchina, E., et al. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200862 · Cited by 10
Self-citation
Allogeneic CAR-T cells for cancer immunotherapy
Chen, X., Gao, Y., & Zhang, Y. (2024) · Immunotherapy · doi:10.1080/1750743x.2024.2408048 · Cited by 10
Current Status of Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma
Jindal, V., Khoury, J., Gupta, R., & Jaiyesimi, I. A. (2020) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000669 · Cited by 10
T Cell Subsets During Early Life and Their Implication in the Treatment of Childhood Acute Lymphoblastic Leukemia
Saghafian‐Hedengren, S., Sverremark‐Ekström, E., & Nilsson, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.582539 · Cited by 11
Current and future perspectives of chimeric antigen receptors against glioblastoma
Zhang, J., & Siller‐Farfán, J. A. (2022) · Immunotherapy Advances · doi:10.1093/immadv/ltac014 · Cited by 11
Clinical Strategies for Enhancing the Efficacy of CAR T-Cell Therapy for Hematological Malignancies
Liu, Q., Liu, Z., Wan, R., & Huang, W. (2022) · Cancers · doi:10.3390/cancers14184452 · Cited by 10
Post-Hematopoietic Cell Transplantation Relapsed Acute Lymphoblastic Leukemia: Current Challenges and Future Directions
Varadarajan, I., Pierce, E. J., Scheuing, L., Morris, A., Chaer, F. E., & Keng, M. K. (2023) · OncoTargets and Therapy · doi:10.2147/ott.s274551 · Cited by 10
Sequential CAR T cell and targeted alpha immunotherapy in disseminated multiple myeloma
Awuah, D., Minnix, M., Caserta, E., Tandoh, T., Adhikarla, V., Poku, E. K., Rockne, R. C., Pichiorri, F., Shively, J. E., & Wang, X. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03461-z · Cited by 10
Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer
Zhu, Y., Zuo, D., Wang, X., Lan, S., He, H., Chen, L., Chen, X., & Feng, M. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05279-9 · Cited by 10
Unravelling the modified T cell receptor through Gen-Next CAR T cell therapy in Glioblastoma: Current status and future challenges
Bhutani, B., Sharma, V., Ganguly, N. K., & Rana, R. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117987 · Cited by 9
Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer
Lundh, S. M., Jung, I.-Y., Dimitri, A. J., Vora, A., Melenhorst, J. J., Jadlowsky, J. K., & Fraietta, J. A. (2020) · Clinical and Experimental Medicine · doi:10.1007/s10238-020-00628-1 · Cited by 10
A novel computer vision‐based assessment of neutrophil chemotaxis in patients with severe infection
Yang, Y., Liu, L., Guo, Z., Huang, J., Li, L., Shao, Y., Song, M., Yang, A., & Sun, B. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1333 · Cited by 10
Self-citation
CAR T cell therapy in solid tumors; with an extensive focus on obstacles and strategies to overcome the challenges
Khorasani, A. B. S., Sanaei, M., Pourbagheri‐Sigaroodi, A., Ghaffari, S. H., & Bashash, D. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108260 · Cited by 10
Preclinical evaluation of chimeric antigen receptor T cells targeting the carcinoembryonic antigen as a potential immunotherapy for gallbladder cancer
López, E., Hidalgo, S., Roa, E., Gómez, J., Truan, C. H., Sanders, E., Carrasco, C., Pacheco, R., Salazar‐Onfray, F., Varas‐Godoy, M., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2225291 · Cited by 9
Engineering CAR-T cells for solid tumors: bispecific antigen targeting, tumor microenvironment modulation, and toxicity control
Premchandani, T., Qutub, M., Tatode, A., Umekar, M. J., Taksande, J., Hussain, U., & Khidkikar, S. R. (2025) · Immunologic Research · doi:10.1007/s12026-025-09687-6 · Cited by 9
Engineered Bacterial Biomaterials for Augmenting Adoptive Immune Cell Therapy Against Solid Tumors
Zhu, C., Sun, Z., Wu, Q., Wang, F., Zhang, L. L., Wang, W., Ding, Y., & Li, H. (2026) · Advanced Materials · doi:10.1002/adma.202522140 · Cited by 9
Overcoming functional and translational challenges of cellular immunotherapies for solid tumors
Chen, Y.-C., Chen, K., Levine, B. L., & Shah, K. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.02.002 · Cited by 9
CAR-based cell therapy: evaluation with bibliometrics and patent analysis
Yuan, Y., Fu, Q., Zhang, Y., Xu, D., Wu, Y., Qiu, Q., & Zhou, W. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1947100 · Cited by 9
Positron Emission Tomography Probes for Imaging Cytotoxic Immune Cells
Amgheib, A., Fu, R., & Aboagye, E. O. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102040 · Cited by 9
Rational design of a Nivolumab-based ANTI-PD-1 single chain variable fragment that blocks the interaction between PD-1 expressed on T-CELLS and PD-L1 ON CHO cells
Shin, J., Raissi, S., Phelan, P., & Bullock, P. A. (2022) · Protein Expression and Purification · doi:10.1016/j.pep.2022.106196 · Cited by 9
Enhanced tumor immunotherapy by polyfunctional CD19-CAR T cells engineered to secrete anti-CD47 single-chain variable fragment
Qiu, Y., Liao, P., Wang, H., Chen, J., Hu, Y., Hu, R., Zhang, H., Li, Z., Cao, M., Yang, Y., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.86632 · Cited by 9
Self-citation
CAR-T-Cell Therapy Based on Immune Checkpoint Modulation in the Treatment of Hematologic Malignancies
Su, M., Zhang, Z., Jiang, P., Wang, X., Tong, X., & Wu, G. (2024) · Cell Transplantation · doi:10.1177/09636897241293964 · Cited by 9
Splice-Switching Antisense Oligonucleotides as a Targeted Intrinsic Engineering Tool for Generating Armored Redirected T Cells
Ceccarello, E., Tabaglio, T., Koh, S., Oei, V., Teo, W. K. L., Jonathan, O. J., Pavesi, A., Chen, Q., Bertoletti, A., Wee, K. B., et al. (2021) · Nucleic Acid Therapeutics · doi:10.1089/nat.2020.0905 · Cited by 10
Production of Therapeutic Single-Chain Variable Fragments (ScFv) in Pichia pastoris
Montoliu‐Gaya, L., & Villegas, S. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1450-1_8 · Cited by 9
An overview of multiplexed analyses of CAR T-cell therapies: insights and potential
DePriest, B. P., Vieira, N., Bidgoli, A., & Paczesny, S. (2021) · Expert Review of Proteomics · doi:10.1080/14789450.2021.1992276 · Cited by 9
CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges
Ren, P., Zhang, C., Li, W., Wang, X., Liang, A., Yang, G., Xu, H., & Ma, P. (2022) · Advanced Biology · doi:10.1002/adbi.202101262 · Cited by 10
Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities
Chen, L., Chen, F., Niu, H., Li, J., Pu, Y., Yang, C., Wang, Y., Huang, R., Li, K., Lei, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.871661 · Cited by 11
RETRACTED ARTICLE: Molecular and therapeutic effect of CRISPR in treating cancer
Rodrigo, S., Senasinghe, K., & Quazi, S. (2023) · Medical Oncology · doi:10.1007/s12032-022-01930-6 · Cited by 10
Retracted
CAR-armed cell therapy for gliomas.
Zhai, Y., Li, G., Jiang, T., & Zhang, W. (2019) · PubMed Central · Cited by 9
Validation of a PD-1/CD28 chimeric switch receptor to augment CAR-T function in dogs with spontaneous B cell lymphoma
Yoshimoto, S., Kudo, A., Rotolo, A., Foos, K. M., Olenick, L. K., Takagi, S., & Mason, N. J. (2024) · iScience · doi:10.1016/j.isci.2024.110863 · Cited by 8
Drug-tolerant persister cells in acute myeloid leukemia: pressing challenge and promising new strategies for treatment
Li, M., Wang, X., He, W., & Zhou, H. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1586552 · Cited by 8
CAR-T Cell Therapy for Prostate Cancer: Current Advances and Future Perspectives
Calabrò, M. L., Ettari, R., Chio, C. D., Luca, F. D., Previti, S., & Zappalà, M. (2025) · Biomedicines · doi:10.3390/biomedicines13102545 · Cited by 8
Nano-/nanobio-technology-enhanced CAR-T cell therapy: engineering the next generation of immunotherapies
Zuo, M., Wang, J., Zhang, W., Xiao, L., Qiao, Z., Li, W., Zhao, J., Xiong, K., Yan, X., & Zhang, K. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.217388 · Cited by 8
Engineering Immunity: Current Progress and Future Directions of CAR-T Cell Therapy
Sioud, M., & Casey, N. P. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020909 · Cited by 9
Novel technologies for improving the safety and efficacy of CAR-T cell therapy
Ohta, K., Sakoda, Y., & Tamada, K. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03478-7 · Cited by 8
Exploration of T cell immune responses by expression of a dominant-negative SHP1 and SHP2
Taylor, J., Bulek, A. M., Gannon, I., Robson, M. P., Kokalaki, E., Grothier, T., McKenzie, C., El-Kholy, M., Stavrou, M., Traynor-White, C., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1119350 · Cited by 8
Chemokine‐Based Injectable Navigation System for Enhancing CAR‐T Cell Therapy Against Solid Tumors
Wan, W., Han, W., Chen, J., Li, Y., Zhao, L., Gao, M., Shen, C., Liu, N., Deng, W., Ma, S., et al. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202401161 · Cited by 8
Rendering NK Cells Antigen-Specific for the Therapy of Solid Tumours
Doeppner, C. A., Binder, A. K., Bremm, F., Feuchter, N., Dörrie, J., & Schaft, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136290 · Cited by 8
Engineered Fragments of the PSMA-Specific 5D3 Antibody and Their Functional Characterization
Nováková, Z., Bělousová, N., Foss, C. A., Havlínová, B., Gresova, M., Das, G., Lisok, A., Přáda, A., Bařinková, M. Š., Hubálek, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186672 · Cited by 8
Combinations of Single Chain Variable Fragments From HIV Broadly Neutralizing Antibodies Demonstrate High Potency and Breadth
van Dorsten, R. T., Wagh, K., Moore, P. L., & Morris, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.734110 · Cited by 8
Augmenting Adoptive T-cell Immunotherapy by Targeting the PD-1/PD-L1 Axis
Lai, J., Beavis, P. A., Li, J., & Darcy, P. K. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-3548 · Cited by 8
Adoptive T-cell Immunotherapy: Perfecting Self-Defenses
Zur-Toledano, R., Adler, G., Shamalov, K., Tal, Y., Ankri, C., & Cohen, C. J. (2022) · Experientia supplementum · doi:10.1007/978-3-030-91311-3_9 · Cited by 9
Glycogen kinase 3 inhibitor nanoformulation as an alternative strategy to inhibit PD-1 immune checkpoint
Badiee, P., Maritz, M. F., & Thierry, B. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121845 · Cited by 8
Anticalin®-based therapeutics: Expanding new frontiers in drug development
Morales‐Kastresana, A., Siegemund, M., Haak, S., Peper-Gabriel, J. K., Neiens, V., & Rothe, C. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.03.009 · Cited by 8
Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor
Joseph, N. S., Tai, Y., Anderson, K. C., & Lonial, S. (2021) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s288840 · Cited by 8
CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies
Mi, J., Xu, J., Zhou, J., Zhao, W., Zhu, C. H., Melenhorst, J. J., & Chen, S. (2021) · Frontiers of Medicine · doi:10.1007/s11684-021-0904-z · Cited by 8
Remote control of CAR T cell therapies by thermal targetingPreprint
Miller, I. C., Sun, L.-K., Harris, A. M., Gamboa, L., Zamat, A. H., & Kwong, G. A. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.26.062703 · Cited by 8
Optimising CAR T therapy for the treatment of solid tumors
Mobark, N., Hull, C., & Maher, J. F. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2421194 · Cited by 7
Chimeric Antigen Receptor T-cell therapy in systemic autoimmune rheumatic diseases: current insights and future prospects
Lee, B.-W., Kwon, E.-J., & Ju, J. H. (2025) · Journal of Rheumatic Diseases · doi:10.4078/jrd.2024.0122 · Cited by 7
Engineered T cells and macrophages: two arms to seize solid tumors
Russo, L., Martino, I. D., Marchetti, M., & Siciliano, V. (2025) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2025.103296 · Cited by 8
Cell therapies against brain tumors: Clinical development and emerging prospects
Fukuta, T., Shaha, S., da Silva‐Candal, A., Zhao, Z., & Mitragotri, S. (2025) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70018 · Cited by 8
Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies
Sun, Y., Yang, H., Xu, Q., Li, X., Lou, J., Duan, J., Xu, J., Liu, Z., Xia, Y., Lin, Z., et al. (2025) · Advanced Science · doi:10.1002/advs.202508754 · Cited by 7
Preclinical evaluation of TIGIT as a target to enhance efficacy and mitigate T cell exhaustion in multiple myeloma following BCMA-CAR-T therapy
Xia, Y., Jian-feng, Z., Guo, R., Shen, X., Shi, M., Shen, N., Fan, L., & Chen, L. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08203-w · Cited by 8
Injectable hydrogels for cancer phototherapy
Xu, Y., Guo, Y., Wu, X., Wang, W., Chen, P., Qu, L., & Dong, X. (2026) · Progress in Materials Science · doi:10.1016/j.pmatsci.2026.101683 · Cited by 7
The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM
Freeburg, N. F., Chafamo, D., Gopikrishna, G., Murphy, R. M., Peng, J. J., Parthasarathy, S., Dumont, S. D., Estrada, E. G., Logun, M. T., Sun, Y., et al. (2026) · Cell · doi:10.1016/j.cell.2026.05.026 · Cited by 7
Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation
Cao, X., Li, J., Lu, P., & Liu, K.-Y. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03398-6 · Cited by 7
Paving the road to make chimeric antigen receptor‐T‐cell therapy effective against solid tumors
Adachi, K., & Tamada, K. (2022) · Cancer Science · doi:10.1111/cas.15552 · Cited by 7
Current perspectives on resistance to chimeric antigen receptor T‐cell therapy and strategies to improve efficacy in B‐cell lymphoma
Ong, S. Y., Chen, Y., Tan, M. S. Y., Ho, A. Y. L., Hwang, W. Y. K., & Lim, F. (2023) · European Journal Of Haematology · doi:10.1111/ejh.13964 · Cited by 7
Rational engineering of an improved adenosine deaminase 2 enzyme for weaponizing T-cell therapies
Cox, J. R., Jennings, M. R., Lenahan, C., Manion, M., Courville, S., & Blazeck, J. (2023) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2023.100394 · Cited by 7
Engineering Improved CAR T Cell Products with A Multi‐Cytokine Particle Platform for Hematologic and Solid Tumors
Lin, H. K., Uricoli, B., Freeman, R., Hossian, A. K. M. N., He, Z., Anderson, J. Y. L., Neffling, M.-R., Legier, J. M., Blake, D. A., Doxie, D. B., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202302425 · Cited by 7
Self-citation
Therapeutic advantage of combinatorial chimeric antigen receptor T cell and chemotherapies
Ward, M. B., Jones, A. B., & Krenciute, G. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.001070 · Cited by 7
Targeting NR4As, a new strategy to fine-tune CAR-T cells against solid tumors
Li, F., & Zhang, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0041-1 · Cited by 7
T-cell receptor and chimeric antigen receptor in solid cancers: current landscape, preclinical data and insight into future developments
Azizi, A. A., Pillai, M. R., & Thistlethwaite, F. C. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000562 · Cited by 7
Chimeric antigen receptor T-cell lymphoma immunotherapy: the next questions
Salaroli, A., Spilleboudt, C., Bron, D., & Lewalle, P. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000671 · Cited by 7
Characterization of a xenograft model for anti-CD19 CAR T cell studies
Ahmadbeigi, N., Alatab, S., Vasei, M., Ranjbar, A., Aghayan, S., Khorsand, A. A., Moradzadeh, K., Darvishyan, Z., Jamali, M., & Muhammadnejad, S. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02626-5 · Cited by 7
Current Status of CAR-T Cell Therapy in Multiple Myeloma
Reguera, J. L., García‐Guerrero, E., & Pérez‐Simón, J. A. (2021) · Hemato · doi:10.3390/hemato2040043 · Cited by 7
Strategies to overcome the side effects of chimeric antigen receptor T cell therapy
Godarzee, M. M., Hussen, B. M., Razmara, E., Hakak‐Zargar, B., Mohajerani, F., Dabiri, H., Rasul, M. F., Ghazimoradi, M. H., Babashah, S., & Sadeghizadeh, M. (2022) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14724 · Cited by 7
Overcoming resistance to anti‐CD19 CAR T‐cell therapy in B‐cell malignancies
Yang, X., Wei, J., & Zhou, J. (2022) · Hematological Oncology · doi:10.1002/hon.3036 · Cited by 7
Advances in Promoting the Efficacy of Chimeric Antigen Receptor T Cells in the Treatment of Hepatocellular Carcinoma
Shen, J., Yang, D., & Ding, Y. (2022) · Cancers · doi:10.3390/cancers14205018 · Cited by 7
Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges
Al-Hujaily, E. M., Al-Sowayan, B. S., Alyousef, Z., Uddin, S., & Alammari, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213696 · Cited by 6
Cellular Kinetics and Biodistribution of Adoptive T Cell Therapies: from Biological Principles to Effects on Patient Outcomes
Li, R., Grosskopf, A. K., Joslyn, L. R., Stefanich, E. G., & Shivva, V. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01017-w · Cited by 6
T cell exhaustion in pediatric B-ALL: current knowledge and future perspectives
Atre, T., & Reid, G. S. D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1531145 · Cited by 6
Advances in immunoPET/SPECT imaging: The role of Fab and F(ab′)2 fragments in theranostics
Huang, W., Zhou, J., Liu, Y., Yang, Y., Saladin, R. J., Hsu, J. C., Cai, W., & Kang, L. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.05.030 · Cited by 6
Immunotherapy for Platinum-Resistant Ovarian Cancer as a Glimmer of Hope
Brancewicz, J., Padzińska-Pruszyńska, I. B., Kubiak, M., & Kucharzewska, P. (2025) · Cells · doi:10.3390/cells14130995 · Cited by 6
SCAN-ACT: adoptive T cell therapy target discovery through single-cell transcriptomics
Testa, S., Pal, A., Subramanian, A., Varma, S., Tang, J. P., Graham, D., Arfan, S., Pan, M., Bui, N. Q., Ganjoo, K. N., et al. (2025) · Genome Medicine · doi:10.1186/s13073-025-01514-9 · Cited by 6
Breakthroughs in immune checkpoint therapy: overcoming NSCLC immune checkpoint therapy resistance with novel techniques
Kang, L., Huang, H.-J., Xu, C., Chen, H., Huang, D., & Jiang, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1630940 · Cited by 7
Mechanistic basis and therapeutic modulation of T cell fitness to enhance CAR-T cell efficacy in hematological malignancies
Makni‐Maalej, K., Alotaibi, S., Fernandes, Q., Ahmed, S. O., Mestiri, S., Bougarn, S., Amir, W., Syed, F., Kharfan‐Dabaja, M. A., Merhi, M., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1762453 · Cited by 6
Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review
Weinstein, B., Muresan, B., Solano, S., de Macedo, A. V., Lee, Y., Su, Y., Ahn, Y., Henriquez, G., Carmago, C., Kim, G.-J., et al. (2021) · INNOVATIONS in pharmacy · doi:10.24926/iip.v12i4.4345 · Cited by 6
Acidity-targeting transition-aided universal chimeric antigen receptor T-cell (ATT-CAR-T) therapy for the treatment of solid tumors
Shi, T., Sun, M., Tuerhong, S., Li, M., Wang, J., Wang, Y., Zheng, Q., Lu, C., Lu, C., Sun, Z., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122607 · Cited by 6
Strategies following failure of CAR-T-cell therapy in non-Hodgkin lymphoma
Zhang, X., Xu, K., Gale, R. P., & Pan, B. (2024) · Bone Marrow Transplantation · doi:10.1038/s41409-024-02463-4 · Cited by 6
Investigation of the enhanced antitumour potency of CD46-specific chimeric antigen receptor-T cells in human colorectal cancer liver metastases after combination with nanotherapeutics
Meng, Q., Xu, J., Wang, J., Zhang, X., Yang, H., Sun, H. X., Wu, S., Aschner, M., Li, X., Zhang, L., et al. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101985 · Cited by 6
Harnessing the Transcriptional Signatures of CAR-T-Cells and Leukemia/Lymphoma Using Single-Cell Sequencing Technologies
Liao, Y., Hsu, S., & Chiou, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042416 · Cited by 7
CAR designs for solid tumors: overcoming hurdles and paving the way for effective immunotherapy
Cui, Y., Luo, M., Gu, C., He, Y., Yao, Y., & Li, P. (2023) · Biophysics Reports · doi:10.52601/bpr.2023.230020 · Cited by 6
Programmed cell death protein-1 inhibitor combined with chimeric antigen receptor T cells in the treatment of relapsed refractory non-Hodgkin lymphoma: A case report
Niu, Z.-Y., Sun, L., Wen, S.-P., Song, Z.-R., Xing, L., Wang, Y., Li, J., Zhang, X.-J., & Wang, F. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i10.2394 · Cited by 6
Approaches for refining and furthering the development of CAR-based T cell therapies for solid malignancies
Hull, C., & Maher, J. F. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1929920 · Cited by 6
Cancer immunotherapy with CAR T cells: well-trodden paths and journey along lesser-known routes
Smole, A. (2022) · Radiology and Oncology · doi:10.2478/raon-2022-0049 · Cited by 8
Immune cell engineering: opportunities in lung cancer therapeutics
Bhargava, A., Mishra, D. K., Tiwari, R. R., Lohiya, N. K., Goryacheva, I. Y., & Mishra, P. K. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00719-2 · Cited by 6
Using Adoptive Cellular Therapy for Localized Protein Secretion
Evans, A. N., Lin, H. K., Hossian, A. K. M. N., & Rafiq, S. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000510 · Cited by 6
Self-citation
DNA-scaffolded biomaterials enable modular and tunable control of cell-based cancer immunotherapiesPreprint
Huang, X., Williams, J. Z., Chang, R., Li, Z., Gai, E., Patterson, D. M., Wei, Y., Lim, W. A., & Desai, T. A. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/587105 · Cited by 6
Self-citation
Chimeric antigen receptor-engineered (CAR)-T cell therapy for metastatic prostate cancer
Tharian, L. R., Verma, S., Feinberg, D. M., Parameswaran, R., & Gupta, S. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217986 · Cited by 5
Novel perspectives on MSLN-targeted cancer therapy: from molecular mechanisms to clinical translation
Wu, Z., Fu, X., Feng, Y., Zeng, R., Qin, H., & Yao, K. (2025) · Cancer Biology & Therapy · doi:10.1080/15384047.2025.2603105 · Cited by 5
CAR-macrophages: a new chapter in cancer immunotherapy
Tang, X., & Xiao, Q. (2026) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2026017 · Cited by 5
From technological iteration to clinical breakthrough: advances of CAR-T cell therapy in autoimmune diseases
Bf, Y., Xu, J., & Cui, Y. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2627057 · Cited by 5
Generating advanced CAR-based therapy for hematological malignancies in clinical practice: targets to cell sources to combinational strategies
Zhou, S., Yang, Y., Jing, Y., & Zhu, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1435635 · Cited by 5
Overcoming chimeric antigen receptor-T (CAR-T) resistance with checkpoint inhibitors: Existing methods, challenges, clinical success, and future prospects : A comprehensive review
Tulsian, K., Thakker, D., & Vyas, V. K. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.141364 · Cited by 5
New CARs on and off the road: challenges and new developments in CAR-T cell therapy
Wehrli, M., & Maus, M. V. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.05.005 · Cited by 5
Simulation of delaminations in composite laminates
Gudimetla, P., Kharidi, A., & Yarlagadda, P. K. D. V. (2009) · QUT ePrints (Queensland University of Technology) · Cited by 5

Authors: Rafiq, S., Yeku, O. O., Jackson, H. J., Purdon, T. J., van Leeuwen, D. G., Drakes, D. J., Song, M., Miele, M. M., Li, Z., Wang, P., Yan, S., Xiang, J., Ma, X., Seshan, V. E., Hendrickson, R. C., Liu, C., & Brentjens, R. J.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Cornell University (US)
Weill Cornell Medicine (US)
Eureka Therapeutics (United States) (US)
Corresponding author: Brentjens, Renier J
ORCID: Rafiq, Sarwish
Yeku, Oladapo O
Purdon, Terence J
van Leeuwen, Dayenne G
Drakes, Dylan J
Song, Mei
Miele, Matthew M
Li, Zhuoning
Yan, Su
Xiang, Jingyi
Ma, Xiaojing
Seshan, Venkatraman E
Hendrickson, Ronald C
Brentjens, Renier J
Venue: Nature Biotechnology
Publisher: Springer Science and Business Media LLC
Published: 2018-08-13
Volume: 36
Issue: 9
Pages: 847-856
ISSN: 0733-222X (ISSN-L)
1087-0156
1546-1696
DOI: 10.1038/nbt.4195
PMC: PMC6126939
OpenAlex: W2886131798
Cited by: 833
References: 46
Citations by year: 2026: 78 · 2025: 94 · 2024: 91 · 2023: 114 · 2022: 123 · 2021: 121 · 2020: 122 · 2019: 72 · 2018: 14
FWCI: 31.01
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature Biotechnology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (1s10od010598-01)
National Cancer Institute (P01CA190174, P50CA192937, P30CA008748)
Topics: Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: chimeric antigen receptor T cells, anti-PD-1 therapy, scFv, chimeric antigen receptor, immune checkpoint blockade, PD-L1, paracrine signaling, autocrine signaling, bystander T cells, tumor microenvironment, hematologic malignancies, solid tumors, CAR T cell safety
MeSH terms: Receptors, Chimeric Antigen, Animals, Humans, T-Lymphocytes, Xenograft Model Antitumor Assays, Mice, Single-Chain Antibodies, Tumor Microenvironment, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks